149 related articles for article (PubMed ID: 27190602)
1. Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors.
Wisniewski JA; Yin J; Teuscher KB; Zhang M; Ji H
ACS Med Chem Lett; 2016 May; 7(5):508-13. PubMed ID: 27190602
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
3. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.
Hoggard LR; Zhang Y; Zhang M; Panic V; Wisniewski JA; Ji H
J Am Chem Soc; 2015 Sep; 137(38):12249-60. PubMed ID: 26352795
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.
Catrow JL; Zhang Y; Zhang M; Ji H
J Med Chem; 2015 Jun; 58(11):4678-92. PubMed ID: 25985283
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction.
Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S
Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304
[TBL] [Abstract][Full Text] [Related]
9. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.
Wang Z; Zhang M; Thompson HM; Ji H
ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435
[TBL] [Abstract][Full Text] [Related]
10. Rational design of small-molecule inhibitors for β-catenin/T-cell factor protein-protein interactions by bioisostere replacement.
Yu B; Huang Z; Zhang M; Dillard DR; Ji H
ACS Chem Biol; 2013 Mar; 8(3):524-9. PubMed ID: 23272635
[TBL] [Abstract][Full Text] [Related]
11. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
Zhang M; Wisniewski JA; Ji H
Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q
Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228
[TBL] [Abstract][Full Text] [Related]
13. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction.
Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M
DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors.
Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q
Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Tcf4 G13ANDE17 binding site to selectively disrupt β-catenin/T-cell factor protein-protein interactions.
Huang Z; Zhang M; Burton SD; Katsakhyan LN; Ji H
ACS Chem Biol; 2014 Jan; 9(1):193-201. PubMed ID: 24191653
[TBL] [Abstract][Full Text] [Related]
17. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.
Wang Z; Zhang M; Wang J; Ji H
J Med Chem; 2019 Apr; 62(7):3617-3635. PubMed ID: 30856332
[TBL] [Abstract][Full Text] [Related]
19. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
20. The Wnt-dependent and Wnt-independent functions of BCL9 in development, tumorigenesis, and immunity: Implications in therapeutic opportunities.
Wu M; Dong H; Xu C; Sun M; Gao H; Bu F; Chen J
Genes Dis; 2024 Mar; 11(2):701-710. PubMed ID: 37692512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
